Statement: Several treatments in the secondary trial are administered by mouth, none of the treatments in the primary trial are given via this route.
Primary_evidence: INTERVENTION 1:    Diagnostic FES: Average FES SUVmean >1.5, no Negative Sites   Patients undergo [^18F] FES PET scan. Patients also undergo standard clinical fludeoxyglucose F 18 (FDG)-PET or FDG-PET/CT scan up to 14 days prior to [^18F] FES PET scan.   Patients begin clinically indicated endocrine therapy.   Patients are followed-up to determine response on the therapy for 6 months using clinical exams, tumor marker assays, conventional imaging and standard clinical FDG PET/CT.   This group represents patients who had positive FES uptake at all disease sites on the baseline diagnostic FES PET scan.   laboratory biomarker analysis: Correlative studies INTERVENTION 2:    Diagnostic FES: Patients With FES Negative Sites of Disease   Patients undergo [^18F] FES PET scan. Patients also undergo standard clinical fludeoxyglucose F 18 (FDG)-PET or FDG-PET/CT scan up to 14 days prior to [^18F] FES PET scan.   Patients begin clinically indicated endocrine therapy.   Patients are followed-up to determine response on the therapy for 6 months using clinical exams, tumor marker assays, conventional imaging and standard clinical FDG PET/CT.   This group represents patients who had some or all disease sites negative for FES uptake on the baseline diagnostic FES PET scan.
Secondary_evidence: INTERVENTION 1:    Treatment (Vorinostat, AI Therapy)   Patients receive vorinostat PO 5 days a week for 3 weeks. Patients also receive AI therapy comprising either anastrozole PO daily, letrozole PO daily, or exemestane PO daily for 4 weeks. Courses repeat every 28 days in the absence of disease progression and unacceptable toxicity.   vorinostat: Given PO   anastrozole: Given PO   letrozole: Given PO   exemestane: Given PO   positron emission tomography: Correlative studies   F-18 16 alpha-fluoroestradiol: Correlative studies   fludeoxyglucose F 18: Correlative studies   laboratory biomarker analysis: Correlative studies